835 results on '"Stary, J."'
Search Results
202. HIGH GRADE GLIOMAS AND DIPG
- Author
-
Classen, C. F., primary, William, D., additional, Linnebacher, M., additional, Farhod, A., additional, Kedr, W., additional, Elsabe, B., additional, Fadel, S., additional, Van Gool, S., additional, De Vleeschouwer, S., additional, Koks, C., additional, Garg, A., additional, Ehrhardt, M., additional, Riva, M., additional, Agostinis, P., additional, Graf, N., additional, Yao, T.-W., additional, Yoshida, Y., additional, Zhang, J., additional, Ozawa, T., additional, James, D., additional, Nicolaides, T., additional, Kebudi, R., additional, Cakir, F. B., additional, Gorgun, O., additional, Agaoglu, F. Y., additional, Darendeliler, E., additional, Al-Kofide, A., additional, Al-Shail, E., additional, Khafaga, Y., additional, Al-Hindi, H., additional, Dababo, M., additional, Haq, A. U., additional, Anas, M., additional, Barria, M. G., additional, Siddiqui, K., additional, Hassounah, M., additional, Ayas, M., additional, van Zanten, S. V., additional, Jansen, M., additional, van Vuurden, D., additional, Huisman, M., additional, Vugts, D., additional, Hoekstra, O., additional, van Dongen, G., additional, Kaspers, G., additional, Cockle, J., additional, Ilett, E., additional, Scott, K., additional, Bruning-Richardson, A., additional, Picton, S., additional, Short, S., additional, Melcher, A., additional, Benesch, M., additional, Warmuth-Metz, M., additional, von Bueren, A. O., additional, Hoffmann, M., additional, Pietsch, T., additional, Kortmann, R.-D., additional, Eyrich, M., additional, Rutkowski, S., additional, Fruhwald, M. C., additional, Faber, J., additional, Kramm, C., additional, Porkholm, M., additional, Valanne, L., additional, Lonnqvist, T., additional, Holm, S., additional, Lannering, B., additional, Riikonen, P., additional, Wojcik, D., additional, Sehested, A., additional, Clausen, N., additional, Harila-Saari, A., additional, Schomerus, E., additional, Thorarinsdottir, H. K., additional, Lahteenmaki, P., additional, Arola, M., additional, Thomassen, H., additional, Saarinen-Pihkala, U. M., additional, Kivivuori, S.-M., additional, Buczkowicz, P., additional, Hoeman, C., additional, Rakopoulos, P., additional, Pajovic, S., additional, Morrison, A., additional, Bouffet, E., additional, Bartels, U., additional, Becher, O., additional, Hawkins, C., additional, Gould, T. W. A., additional, Rahman, C. V., additional, Smith, S. J., additional, Barrett, D. A., additional, Shakesheff, K. M., additional, Grundy, R. G., additional, Rahman, R., additional, Barua, N., additional, Cronin, D., additional, Gill, S., additional, Lowisl, S., additional, Hochart, A., additional, Maurage, C.-A., additional, Rocourt, N., additional, Vinchon, M., additional, Kerdraon, O., additional, Escande, F., additional, Grill, J., additional, Pick, V. K., additional, Leblond, P., additional, Burzynski, G., additional, Janicki, T., additional, Burzynski, S., additional, Marszalek, A., additional, Ramani, N., additional, Zaky, W., additional, Kannan, G., additional, Morani, A., additional, Sandberg, D., additional, Ketonen, L., additional, Maher, O., additional, Corrales-Medina, F., additional, Meador, H., additional, Khatua, S., additional, Brassesco, M., additional, Delsin, L., additional, Roberto, G., additional, Silva, C., additional, Ana, L., additional, Rego, E., additional, Scrideli, C., additional, Umezawa, K., additional, Tone, L., additional, Kim, S. J., additional, Kim, C.-Y., additional, Kim, I.-A., additional, Han, J. H., additional, Choi, B.-S., additional, Ahn, H. S., additional, Choi, H. S., additional, Haque, F., additional, Layfield, R., additional, Grundy, R., additional, Gandola, L., additional, Pecori, E., additional, Biassoni, V., additional, Schiavello, E., additional, Chiruzzi, C., additional, Spreafico, F., additional, Modena, P., additional, Bach, F., additional, Pignoli, E., additional, Massimino, M., additional, Drogosiewicz, M., additional, Dembowska-Baginska, B., additional, Jurkiewicz, E., additional, Filipek, I., additional, Perek-Polnik, M., additional, Swieszkowska, E., additional, Perek, D., additional, Bender, S., additional, Jones, D. T., additional, Warnatz, H.-J., additional, Hutter, B., additional, Zichner, T., additional, Gronych, J., additional, Korshunov, A., additional, Eils, R., additional, Korbel, J. O., additional, Yaspo, M.-L., additional, Lichter, P., additional, Pfister, S. M., additional, Yadavilli, S., additional, Becher, O. J., additional, Kambhampati, M., additional, Packer, R. J., additional, Nazarian, J., additional, Lechon, F. C., additional, Fowkes, L., additional, Khabra, K., additional, Martin-Retortillo, L. M., additional, Marshall, L. V., additional, Vaidya, S., additional, Koh, D.-M., additional, Leach, M. O., additional, Pearson, A. D., additional, Zacharoulis, S., additional, Schrey, D., additional, Barone, G., additional, Panditharatna, E., additional, Stampar, M., additional, Siu, A., additional, Gordish-Dressman, H., additional, Devaney, J., additional, Hwang, E. I., additional, Chung, A. H., additional, Mittapalli, R. K., additional, Elmquist, W. F., additional, Castel, D., additional, Debily, M.-A., additional, Philippe, C., additional, Truffaux, N., additional, Taylor, K., additional, Calmon, R., additional, Boddaert, N., additional, Le Dret, L., additional, Saulnier, P., additional, Lacroix, L., additional, Mackay, A., additional, Jones, C., additional, Puget, S., additional, Sainte-Rose, C., additional, Blauwblomme, T., additional, Varlet, P., additional, Entz-Werle, N., additional, Maugard, C., additional, Bougeard, G., additional, Nguyen, A., additional, Chenard, M. P., additional, Schneider, A., additional, Gaub, M. P., additional, Tsoli, M., additional, Vanniasinghe, A., additional, Luk, P., additional, Dilda, P., additional, Haber, M., additional, Hogg, P., additional, Ziegler, D., additional, Simon, S., additional, Monje, M., additional, Gurova, K., additional, Gudkov, A., additional, Zapotocky, M., additional, Churackova, M., additional, Malinova, B., additional, Zamecnik, J., additional, Kyncl, M., additional, Tichy, M., additional, Puchmajerova, A., additional, Stary, J., additional, Sumerauer, D., additional, Boult, J., additional, Vinci, M., additional, Perryman, L., additional, Box, G., additional, Jury, A., additional, Popov, S., additional, Ingram, W., additional, Eccles, S., additional, Robinson, S., additional, Emir, S., additional, Demir, H. A., additional, Bayram, C., additional, Cetindag, F., additional, Kabacam, G. B., additional, Fettah, A., additional, Li, J., additional, Jamin, Y., additional, Cummings, C., additional, Bamber, J., additional, Sinkus, R., additional, Nandhabalan, M., additional, Bjerke, L., additional, Burford, A., additional, von Bueren, A., additional, Baudis, M., additional, Clarke, P., additional, Collins, I., additional, Workman, P., additional, Olaciregui, N., additional, Mora, J., additional, Carcaboso, A., additional, Bullock, A., additional, Alonso, M., additional, de Torres, C., additional, Cruz, O., additional, Pencreach, E., additional, Moussalieh, F. M., additional, Guenot, D., additional, Namer, I., additional, Pollack, I., additional, Jakacki, R., additional, Butterfield, L., additional, Hamilton, R., additional, Panigrahy, A., additional, Potter, D., additional, Connelly, A., additional, Dibridge, S., additional, Whiteside, T., additional, Okada, H., additional, Ahsan, S., additional, Raabe, E., additional, Haffner, M., additional, Warren, K., additional, Quezado, M., additional, Ballester, L., additional, Eberhart, C., additional, Rodriguez, F., additional, Ramachandran, C., additional, Nair, S., additional, Quirrin, K.-W., additional, Khatib, Z., additional, Escalon, E., additional, Melnick, S., additional, Classen, C. F., additional, Hofmann, M., additional, Schmid, I., additional, Simon, T., additional, Maass, E., additional, Russo, A., additional, Fleischhack, G., additional, Becker, M., additional, Hauch, H., additional, Sander, A., additional, Grasso, C., additional, Berlow, N., additional, Liu, L., additional, Davis, L., additional, Huang, E., additional, Woo, P., additional, Tang, Y., additional, Ponnuswami, A., additional, Chen, S., additional, Huang, Y., additional, Hutt-Cabezas, M., additional, Dret, L., additional, Meltzer, P., additional, Mao, H., additional, Abraham, J., additional, Fouladi, M., additional, Svalina, M. N., additional, Wang, N., additional, Hulleman, E., additional, Li, X.-N., additional, Keller, C., additional, Spellman, P. T., additional, Pal, R., additional, Jansen, M. H. A., additional, Sewing, A. C. P., additional, Lagerweij, T., additional, Vuchts, D. J., additional, van Vuurden, D. G., additional, Caretti, V., additional, Wesseling, P., additional, Kaspers, G. J. L., additional, Cohen, K., additional, Pearl, M., additional, Kogiso, M., additional, Zhang, L., additional, Qi, L., additional, Lindsay, H., additional, Lin, F., additional, Berg, S., additional, Muscal, J., additional, Amayiri, N., additional, Tabori, U., additional, Campbel, B., additional, Bakry, D., additional, Aronson, M., additional, Durno, C., additional, Gallinger, S., additional, Malkin, D., additional, Qaddumi, I., additional, Musharbash, A., additional, Swaidan, M., additional, Al-Hussaini, M., additional, Shandilya, S., additional, McCully, C., additional, Murphy, R., additional, Akshintala, S., additional, Cole, D., additional, Macallister, R. P., additional, Cruz, R., additional, Widemann, B., additional, Salloum, R., additional, Smith, A., additional, Glaunert, M., additional, Ramkissoon, A., additional, Peterson, S., additional, Baker, S., additional, Chow, L., additional, Sandgren, J., additional, Pfeifer, S., additional, Popova, S., additional, Alafuzoff, I., additional, de Stahl, T. D., additional, Pietschmann, S., additional, Kerber, M. J., additional, Zwiener, I., additional, Henke, G., additional, Muller, K., additional, Sieow, N. Y.-F., additional, Hoe, R. H. M., additional, Tan, A. M., additional, Chan, M. Y., additional, Soh, S. Y., additional, Burrell, K., additional, Chornenkyy, Y., additional, Remke, M., additional, Golbourn, B., additional, Barzczyk, M., additional, Taylor, M., additional, Rutka, J., additional, Dirks, P., additional, Zadeh, G., additional, Agnihotri, S., additional, Hashizume, R., additional, Ihara, Y., additional, Andor, N., additional, Chen, X., additional, Lerner, R., additional, Huang, X., additional, Tom, M., additional, Solomon, D., additional, Mueller, S., additional, Petritsch, C., additional, Zhang, Z., additional, Gupta, N., additional, Waldman, T., additional, Dujua, A., additional, Co, J., additional, Hernandez, F., additional, Doromal, D., additional, Hegde, M., additional, Wakefield, A., additional, Brawley, V., additional, Grada, Z., additional, Byrd, T., additional, Chow, K., additional, Krebs, S., additional, Heslop, H., additional, Gottschalk, S., additional, Yvon, E., additional, Ahmed, N., additional, Cornilleau, G., additional, Paulsson, J., additional, Andreiuolo, F., additional, Guerrini-Rousseau, L., additional, Geoerger, B., additional, Vassal, G., additional, Ostman, A., additional, Parsons, D. W., additional, Trevino, L. R., additional, Gao, F., additional, Shen, X., additional, Hampton, O., additional, Kosigo, M., additional, Baxter, P. A., additional, Su, J. M., additional, Chintagumpala, M., additional, Dauser, R., additional, Adesina, A., additional, Plon, S. E., additional, Wheeler, D. A., additional, Lau, C. C., additional, Gielen, G., additional, Muehlen, A. z., additional, Kwiecien, R., additional, Wolff, J., additional, Lulla, R. R., additional, Laskowski, J., additional, Goldman, S., additional, Gopalakrishnan, V., additional, Fangusaro, J., additional, Kieran, M., additional, Fontebasso, A., additional, Papillon-Cavanagh, S., additional, Schwartzentruber, J., additional, Nikbakht, H., additional, Gerges, N., additional, Fiset, P.-O., additional, Bechet, D., additional, Faury, D., additional, De Jay, N., additional, Ramkissoon, L., additional, Corcoran, A., additional, Jones, D., additional, Sturm, D., additional, Johann, P., additional, Tomita, T., additional, Nagib, M., additional, Bendel, A., additional, Goumnerova, L., additional, Bowers, D. C., additional, Leonard, J. R., additional, Rubin, J. B., additional, Alden, T., additional, DiPatri, A., additional, Browd, S., additional, Leary, S., additional, Jallo, G., additional, Prados, M. D., additional, Banerjee, A., additional, Carret, A.-S., additional, Ellezam, B., additional, Crevier, L., additional, Klekner, A., additional, Bognar, L., additional, Hauser, P., additional, Garami, M., additional, Myseros, J., additional, Dong, Z., additional, Siegel, P. M., additional, Gump, W., additional, Ayyanar, K., additional, Ragheb, J., additional, Krieger, M., additional, Kiehna, E., additional, Robison, N., additional, Harter, D., additional, Gardner, S., additional, Handler, M., additional, Foreman, N., additional, Brahma, B., additional, MacDonald, T., additional, Malkin, H., additional, Chi, S., additional, Manley, P., additional, Bandopadhayay, P., additional, Greenspan, L., additional, Ligon, A., additional, Albrecht, S., additional, Ligon, K. L., additional, Majewski, J., additional, Jabado, N., additional, Cordero, F., additional, Halvorson, K., additional, Taylor, I., additional, Hutt, M., additional, Weingart, M., additional, Price, A., additional, Kantar, M., additional, Onen, S., additional, Kamer, S., additional, Turhan, T., additional, Kitis, O., additional, Ertan, Y., additional, Cetingul, N., additional, Anacak, Y., additional, Akalin, T., additional, Ersahin, Y., additional, Mason, G., additional, Ho, C., additional, Crozier, F., additional, Vezina, G., additional, Packer, R., additional, Hwang, E., additional, Gilheeney, S., additional, Millard, N., additional, DeBraganca, K., additional, Khakoo, Y., additional, Kramer, K., additional, Wolden, S., additional, Donzelli, M., additional, Fischer, C., additional, Petriccione, M., additional, Dunkel, I., additional, Afzal, S., additional, Fleming, A., additional, Larouche, V., additional, Zelcer, S., additional, Johnston, D. L., additional, Kostova, M., additional, Mpofu, C., additional, Decarie, J.-C., additional, Strother, D., additional, Lafay-Cousin, L., additional, Eisenstat, D., additional, Fryer, C., additional, Hukin, J., additional, Hsu, M., additional, Lasky, J., additional, Moore, T., additional, Liau, L., additional, Davidson, T., additional, Prins, R., additional, Hassal, T., additional, Baugh, J., additional, Kirkendall, J., additional, Doughman, R., additional, Leach, J., additional, Jones, B., additional, Miles, L., additional, Hargrave, D., additional, Jacques, T., additional, Savage, S., additional, Saunders, D., additional, Wallace, R., additional, Flutter, B., additional, Morgenestern, D., additional, Blanco, E., additional, Howe, K., additional, Lowdell, M., additional, Samuel, E., additional, Michalski, A., additional, Anderson, J., additional, Arakawa, Y., additional, Umeda, K., additional, Watanabe, K.-i., additional, Mizowaki, T., additional, Hiraoka, M., additional, Hiramatsu, H., additional, Adachi, S., additional, Kunieda, T., additional, Takagi, Y., additional, Miyamoto, S., additional, Venneti, S., additional, Santi, M., additional, Felicella, M. M., additional, Sullivan, L. M., additional, Dolgalev, I., additional, Martinez, D., additional, Perry, A., additional, Lewis, P. W., additional, Allis, D. C., additional, Thompson, C. B., additional, and Judkins, A. R., additional
- Published
- 2014
- Full Text
- View/download PDF
203. Mapping epigenetic regulator gene mutations in cytogenetically normal pediatric acute myeloid leukemia
- Author
-
Valerio, D. G., primary, Katsman-Kuipers, J. E., additional, Jansen, J. H., additional, Verboon, L. J., additional, de Haas, V., additional, Stary, J., additional, Baruchel, A., additional, Zimmermann, M., additional, Pieters, R., additional, Reinhardt, D., additional, van den Heuvel-Eibrink, M. M., additional, and Zwaan, C. M., additional
- Published
- 2014
- Full Text
- View/download PDF
204. T-cell receptor Vβ skewing frequently occurs in refractory cytopenia of childhood and is associated with an expansion of effector cytotoxic T cells: a prospective study by EWOG-MDS
- Author
-
Aalbers, A M, primary, van den Heuvel-Eibrink, M M, additional, Baumann, I, additional, Beverloo, H B, additional, Driessen, G J, additional, Dworzak, M, additional, Fischer, A, additional, Göhring, G, additional, Hasle, H, additional, Locatelli, F, additional, De Moerloose, B, additional, Noellke, P, additional, Schmugge, M, additional, Stary, J, additional, Yoshimi, A, additional, Zecca, M, additional, Zwaan, C M, additional, van Dongen, J J M, additional, Pieters, R, additional, Niemeyer, C M, additional, van der Velden, V H J, additional, and Langerak, A W, additional
- Published
- 2014
- Full Text
- View/download PDF
205. A new conditioning regimen for patients with refractory anemia and congenital disorders
- Author
-
Strahm, B., Greil, J., Kremens, B., Peters, C., Stary, J., Hermann Josef Vormoor, Zintl, F., Rogge, T., Locatelli, F., and Niemeyer, Cm
- Subjects
Medizin - Published
- 2003
206. Refractory anemia in childhood: a retrospective analysis of 67 patients with particular reference to monosomy 7
- Author
-
Kardos, G., Bauman, I., Passmore, S.J., Locatelli, F., Hasle, H., Schultz, K.R., Stary, J., Schmidt-Gräff, A., Fisher, A., Harbott, J., Chessells, J.M., Hann, I., Fenu, S., Rajnoldi, A.C., Kerndrup, G.B., and m.fl.
- Published
- 2003
207. Refractory anemia in childhood:A retrospective analysis of 67 cases with particular reference to monosomy 7
- Author
-
Kardos, G., Baumann, I., Passmore, S.J., Locatelli, F., Hasle, H., Schultz, K.R., Stary, J., Schmitt-Gräff, A., Fischer, A., Harbott, J., Chessells, J.M., Hann, I., Fenu, S., Cantu Rajnoldi, A., Kerndrup, G., van Wering, E.R., Rogge, T., Nöllke, P., and Niemeyer, C.M.
- Published
- 2003
208. CD2-positive B-cell precursor acute lymphoblastic leukemia with an early switch to the monocytic lineage
- Author
-
Slamova, L, primary, Starkova, J, additional, Fronkova, E, additional, Zaliova, M, additional, Reznickova, L, additional, van Delft, F W, additional, Vodickova, E, additional, Volejnikova, J, additional, Zemanova, Z, additional, Polgarova, K, additional, Cario, G, additional, Figueroa, M, additional, Kalina, T, additional, Fiser, K, additional, Bourquin, J P, additional, Bornhauser, B, additional, Dworzak, M, additional, Zuna, J, additional, Trka, J, additional, Stary, J, additional, Hrusak, O, additional, and Mejstrikova, E, additional
- Published
- 2013
- Full Text
- View/download PDF
209. miR-9 is a tumor suppressor in pediatric AML with t(8;21)
- Author
-
Emmrich, S, primary, Katsman-Kuipers, J E, additional, Henke, K, additional, Khatib, M E, additional, Jammal, R, additional, Engeland, F, additional, Dasci, F, additional, Zwaan, C M, additional, den Boer, M L, additional, Verboon, L, additional, Stary, J, additional, Baruchel, A, additional, de Haas, V, additional, Danen-van Oorschot, A A, additional, Fornerod, M, additional, Pieters, R, additional, Reinhardt, D, additional, Klusmann, J H, additional, and van den Heuvel-Eibrink, M M, additional
- Published
- 2013
- Full Text
- View/download PDF
210. Pediciidae
- Author
-
Petersen, F.T., de Jong, H., Stary, J., and Systematische en Geografische Dierkunde (inactive) (IBED, FNWI)
- Published
- 2001
211. Spliceosomal gene aberrations are rare, coexist with oncogenic mutations, and are unlikely to exert a driver effect in childhood MDS and JMML
- Author
-
Hirabayashi, S. (Shinsuke), Flotho, C. (Christian), Moetter, J. (Jessica), Heuser, M. (Michael), Hasle, H. (Henrik), Gruhn, B. (Bernd), Klingebiel, T. (Thomas), Thol, F. (Felicitas), Schlegelberger, B. (Brigitte), Baumann, I. (Irith), Strahm, B. (Brigitte), Stary, J. (Jan), Locatelli, F. (Franco), Zecca, M. (Marco), Bergstraesser, E. (Eva), Dworzak, M.N. (Michael), Heuvel-Eibrink, M.M. (Marry) van den, Moerloose, B. (Barbara) de, Ogawa, S. (Susumu), Niemeyer, C.M. (Charlotte), Wlodarski, M. (Marcin), Hirabayashi, S. (Shinsuke), Flotho, C. (Christian), Moetter, J. (Jessica), Heuser, M. (Michael), Hasle, H. (Henrik), Gruhn, B. (Bernd), Klingebiel, T. (Thomas), Thol, F. (Felicitas), Schlegelberger, B. (Brigitte), Baumann, I. (Irith), Strahm, B. (Brigitte), Stary, J. (Jan), Locatelli, F. (Franco), Zecca, M. (Marco), Bergstraesser, E. (Eva), Dworzak, M.N. (Michael), Heuvel-Eibrink, M.M. (Marry) van den, Moerloose, B. (Barbara) de, Ogawa, S. (Susumu), Niemeyer, C.M. (Charlotte), and Wlodarski, M. (Marcin)
- Abstract
Somatic mutations of the spliceosomal machinery occur frequently in adult patients with myelodysplastic syndrome (MDS). We resequenced SF3B1, U2AF35, and SRSF2 in 371 children with MDS or juvenile myelomonocytic leukemia. We found missense mutations in 2 juvenile myelomonocytic leukemia cases and in 1 child with systemic mastocytosis with MDS. In 1 juvenile myelomonocytic leukemia patient, the SRSF2 mutation that initially coexisted with an oncogenic NRAS mutation was absent at relapse, whereas the NRAS mutation persisted and a second, concomitant NRAS mutation later emerged. The patient with systemic mastocytosis and MDS carried both mutated U2AF35 and KIT in a single clone as confirmed by clonal sequencing. In the adult MDS patients sequenced for control purposes, we detected previously reported mutations in 7/30 and a novel SRSF2 deletion (c.284-307del) in 3 of 30 patients. These findings implicate that spliceosome mutations are rare in pediatric MDS and juvenile myelomonocytic leukemia and are unlikely to operate as driver mutations.
- Published
- 2012
- Full Text
- View/download PDF
212. Diagnosis and management of acute myeloid leukemia in children and adolescents: Recommendations from an international expert panel
- Author
-
Creutzig, U., Heuvel-Eibrink, M.M. (Marry) van den, Gibson, B. (Brenda), Dworzak, M.N. (Michael), Adachi, S. (Susumu), Bont, E.S.J.M. (Eveline) de, Harbott, J. (Jochen), Hasle, H. (Henrik), Johnston, D. (Donna), Kinoshita, E. (Eri), Lehrnbecher, T. (Thomas), Leverger, G. (Guy), Mejstříková, E. (Ester), Meshinchi, S. (S.), Pession, A. (Andrea), Raimondi, S.C. (Susana), Sung, L. (Lillian), Stary, J. (Jan), Zwaan, C.M. (Michel), Kaspers, G.J.L. (Gertjan), Reinhardt, D. (Dirk), Creutzig, U., Heuvel-Eibrink, M.M. (Marry) van den, Gibson, B. (Brenda), Dworzak, M.N. (Michael), Adachi, S. (Susumu), Bont, E.S.J.M. (Eveline) de, Harbott, J. (Jochen), Hasle, H. (Henrik), Johnston, D. (Donna), Kinoshita, E. (Eri), Lehrnbecher, T. (Thomas), Leverger, G. (Guy), Mejstříková, E. (Ester), Meshinchi, S. (S.), Pession, A. (Andrea), Raimondi, S.C. (Susana), Sung, L. (Lillian), Stary, J. (Jan), Zwaan, C.M. (Michel), Kaspers, G.J.L. (Gertjan), and Reinhardt, D. (Dirk)
- Abstract
Despite major improvements in outcome over the past decades, acute myeloid leukemia (AML) remains a life-threatening malignancy in children, with current survival rates of ∼ 70%. State-of-the-art
- Published
- 2012
- Full Text
- View/download PDF
213. Role of MRD in Ph+ Pediatric Acute Lymphoblastic Leukemia Patients Treated with and without Tirosine Kinase Inhibitor in the Esphall Study
- Author
-
Cazzaniga, G, Schrappe, M, Lorenzo, P, Castor, A, Lucchini, G, Gandemer, V, Pieters, R, Stary, J, Escherich, G, Hancock, J, Arico', M, Röttgers, S, Saha, V, Biondi, A, Valsecchi, M, BIONDI, ANDREA, VALSECCHI, MARIA GRAZIA, Cazzaniga, G, Schrappe, M, Lorenzo, P, Castor, A, Lucchini, G, Gandemer, V, Pieters, R, Stary, J, Escherich, G, Hancock, J, Arico', M, Röttgers, S, Saha, V, Biondi, A, Valsecchi, M, BIONDI, ANDREA, and VALSECCHI, MARIA GRAZIA
- Published
- 2012
214. Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study
- Author
-
Biondi, A, Schrappe, M, De Lorenzo, P, Castor, A, Lucchini, G, Gandemer, V, Pieters, R, Stary, J, Escherich, G, Campbell, M, Li, C, Vora, A, Aricò, M, Röttgers, S, Saha, V, Valsecchi, M, BIONDI, ANDREA, VALSECCHI, MARIA GRAZIA, Li, CK, Biondi, A, Schrappe, M, De Lorenzo, P, Castor, A, Lucchini, G, Gandemer, V, Pieters, R, Stary, J, Escherich, G, Campbell, M, Li, C, Vora, A, Aricò, M, Röttgers, S, Saha, V, Valsecchi, M, BIONDI, ANDREA, VALSECCHI, MARIA GRAZIA, and Li, CK
- Abstract
Background: Trials of imatinib have provided evidence of activity in adults with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (ALL), but the drug's role when given with multidrug chemotherapy to children is unknown. This study assesses the safety and efficacy of oral imatinib in association with a Berlin-Frankfurt-Munster intensive chemotherapy regimen and allogeneic stem-cell transplantation for paediatric patients with Philadelphia-chromosome-positive ALL. Methods: Patients aged 1-18 years recruited to national trials of front-line treatment for ALL were eligible if they had t(9;22)(q34;q11). Patients with abnormal renal or hepatic function, or an active systemic infection, were ineligible. Patients were enrolled by ten study groups between 2004 and 2009, and were classified as good risk or poor risk according to early response to induction treatment. Good-risk patients were randomly assigned by a web-based system with permuted blocks (size four) to receive post-induction imatinib with chemotherapy or chemotherapy only in a 1:1 ratio, while all poor-risk patients received post-induction imatinib with chemotherapy. Patients were stratified by study group. The chemotherapy regimen was modelled on a Berlin-Frankfurt-Munster high-risk backbone; all received four post-induction blocks of chemotherapy after which they became eligible for stem-cell transplantation. The primary endpoints were disease-free survival at 4 years in the good-risk group and event-free survival at 4 years in the poor-risk group, analysed by intention to treat and a secondary analysis of patients as treated. The trial is registered with EudraCT (2004-001647-30) and ClinicalTrials.gov, number NCT00287105. Findings: Between Jan 1, 2004, and Dec 31, 2009, we screened 229 patients and enrolled 178: 108 were good risk and 70 poor risk. 46 good-risk patients were assigned to receive imatinib and 44 to receive no imatinib. Median follow-up was 3·1 years (IQR 2·0-4·6). 4-year disease-fr
- Published
- 2012
215. The state of research into children with cancer across Europe : new policies for a new decade
- Author
-
Pritchard-Jones, K, Lewison, G, Camporesi, S, Vassal, G, Ladenstein, R, Benoit, Y, Predojevic, Js, Sterba, J, Stary, J, Eckschlager, T, Schroeder, H, Doz, F, Creutzig, U, Klingebiel, T, Kosmidis, Hv, Garami, M, Pieters, R, O'Meara, A, Dini, G, Riccardi, R, Rascon, J, Rageliene, L, Calvagna, V, Czauderna, P, Kowalczyk, Jr, Gil-da-Costa, Mj, Norton, L, Pereira, F, Janic, D, Puskacova, J, Jazbec, J, Canete, A, Hjorth, L, Ljungman, Gustaf, Kutluk, T, Morland, B, Stevens, M, Walker, D, Sullivan, R, Pritchard-Jones, K, Lewison, G, Camporesi, S, Vassal, G, Ladenstein, R, Benoit, Y, Predojevic, Js, Sterba, J, Stary, J, Eckschlager, T, Schroeder, H, Doz, F, Creutzig, U, Klingebiel, T, Kosmidis, Hv, Garami, M, Pieters, R, O'Meara, A, Dini, G, Riccardi, R, Rascon, J, Rageliene, L, Calvagna, V, Czauderna, P, Kowalczyk, Jr, Gil-da-Costa, Mj, Norton, L, Pereira, F, Janic, D, Puskacova, J, Jazbec, J, Canete, A, Hjorth, L, Ljungman, Gustaf, Kutluk, T, Morland, B, Stevens, M, Walker, D, and Sullivan, R
- Abstract
Overcoming childhood cancers is critically dependent on the state of research. Understanding how, with whom and what the research community is doing with childhood cancers is essential for ensuring the evidence-based policies at national and European level to support children, their families and researchers. As part of the European Union funded EUROCANCERCOMS project to study and integrate cancer communications across Europe, we have carried out new research into the state of research in childhood cancers. We are very grateful for all the support we have received from colleagues in the European paediatric oncology community, and in particular from Edel Fitzgerald and Samira Essiaf from the SIOP Europe office. This report and the evidence-based policies that arise from it come at a important junction for Europe and its Member States. They provide a timely reminder that research into childhood cancers is critical and needs sustainable long-term support.
- Published
- 2011
- Full Text
- View/download PDF
216. Aberrant DNA methylation characterizes juvenile myelomonocytic leukemia with poor outcome
- Author
-
Olk-Batz, C. (Christiane), Poetsch, A.R. (Anna), Nöllke, P. (Peter), Claus, R. (Rainer), Zucknick, M. (Manuela), Sandrock, I. (Inga), Witte, T. (Tania), Strahm, B. (Brigitte), Hasle, H. (Henrik), Zecca, M. (Marco), Stary, J. (Jan), Bergstraesser, E. (Eva), Moerloose, B. (Barbara) de, Trebo, M. (Monica), Heuvel-Eibrink, M.M. (Marry) van den, Wojcik, D. (Dorota), Locatelli, F. (Franco), Plass, C. (Christoph), Niemeyer, C.M. (Charlotte), Flotho, C. (Christian), Olk-Batz, C. (Christiane), Poetsch, A.R. (Anna), Nöllke, P. (Peter), Claus, R. (Rainer), Zucknick, M. (Manuela), Sandrock, I. (Inga), Witte, T. (Tania), Strahm, B. (Brigitte), Hasle, H. (Henrik), Zecca, M. (Marco), Stary, J. (Jan), Bergstraesser, E. (Eva), Moerloose, B. (Barbara) de, Trebo, M. (Monica), Heuvel-Eibrink, M.M. (Marry) van den, Wojcik, D. (Dorota), Locatelli, F. (Franco), Plass, C. (Christoph), Niemeyer, C.M. (Charlotte), and Flotho, C. (Christian)
- Abstract
Aberrant DNA methylation contributes to the malignant phenotype in virtually all types of cancer, including myeloid leukemia. We hypothesized that CpG island hypermethylation also occurs in juvenile myelomonocytic leukemia (JMML) and investigated whether it is associated with clinical, hematologic, or prognostic features. Based on quantitative measurements of DNA methylation in 127 JMML cases using mass spectrometry (MassARRAY), we identified 4 gene CpG islands with frequent hypermethylation: BMP4 (36% of patients), CALCA (54%), CDKN2B (22%), and RARB (13%). Hypermethylation was significantly associated with poor prognosis: when the methylation data were transformed into prognostic scores using a LASSO Cox regression model, the 5-year overall survival was 0.41 for patients in the top tertile of scores versus 0.72 in the lowest score tertile (P = .002). Among patients given allogeneic hematopoietic stem cell transplantation, the 5-year cumulative incidence of relapse was 0.52 in the highest versus 0.10 in the lowest score tertile (P = .007).
- Published
- 2011
- Full Text
- View/download PDF
217. Integrative analysis of type-I and type-II aberrations underscores the genetic heterogeneity of pediatric acute myeloid leukemia
- Author
-
Balgobind, B.V. (Brian), Hollink, I.H.I.M. (Iris), Arentsen-Peters, T.C.J.M. (Susan), Zimmermann, M. (Martin), Harbott, J. (Jochen), Beverloo, H.B. (Berna), Bergh, A.R.M. (Anne) von, Cloos, J. (Jacqueline), Kaspers, G.J.L. (Gertjan), Haas, V. (Valerie) de, Zemanová, Z. (Zuzana), Stary, J. (Jan), Cayuela, J.M. (Jean Michel), Baruchel, A. (André), Creutzig, U. (Ursula), Reinhardt, D. (Dirk), Pieters, R. (Rob), Zwaan, C.M. (Michel), Heuvel-Eibrink, M.M. (Marry) van den, Balgobind, B.V. (Brian), Hollink, I.H.I.M. (Iris), Arentsen-Peters, T.C.J.M. (Susan), Zimmermann, M. (Martin), Harbott, J. (Jochen), Beverloo, H.B. (Berna), Bergh, A.R.M. (Anne) von, Cloos, J. (Jacqueline), Kaspers, G.J.L. (Gertjan), Haas, V. (Valerie) de, Zemanová, Z. (Zuzana), Stary, J. (Jan), Cayuela, J.M. (Jean Michel), Baruchel, A. (André), Creutzig, U. (Ursula), Reinhardt, D. (Dirk), Pieters, R. (Rob), Zwaan, C.M. (Michel), and Heuvel-Eibrink, M.M. (Marry) van den
- Abstract
Background Several studies of pediatric acute myeloid leukemia have described the various type-I or type- II aberrations and their relationship with clinical outcome. However, there has been no recent comprehensive overview of these genetic berrations in one large pediatric acute myeloid leukemia cohort. Design and Methods We studied the different genetic aberrations, their associations and their impact on prognosis in a large pediatric acute myeloid leukemia series (n=506). Karyotypes were studied, and hotspot regions of NPM1, CEPBA, MLL, WT1, FLT3, N-RAS, K-RAS, PTPN11 and KIT were screened for mutations of available samples. The mutational status of all type-I and type-II aberrations was available in 330 and 263 cases, respectively. Survival analysis was performed in a subset (n=385) treated on consecutive acute myeloid leukemia Berlin-Frankfurt-Munster Study Group and Dutch Childhood Oncology Group treatment protocols. Results Genetic aberrations were associated with specific clinical characteristics, e.g. significantly higher diagnostic white blood cell counts in MLL-rearranged, WT1-mutated and FLT3-ITD-positive acute myeloid leukemia. Furthermore, there was a significant difference in the distribution of these aberrations between children below and above the age of two years. Non-random associations, e.g. KIT mutations with core-binding factor acute myeloid leukemia, and FLT3-ITD with t(15;17)(q22;q21), NPM1- and WT1-mutated acute myeloid leukemia, respectively, were observed. Multivariate analysis revealed a 'favorable karyotype', i.e. t(15;17)(q22;q21), t(8;21)(q22;q22) and inv(16)(p13q22)/t(16;16)(p13;q22). NPM1 and CEBPA double mutations were independent factors for favorable event-free survival. WT1 mutations combined with FLT3-ITD showed the worst outcome for 5-year overall survival (22±14%) and 5-year eventfree survival (20±13%), although it was not an independent factor in multivariate analysis. Conclusions Integrative analysis of type-I and type-II ab
- Published
- 2011
- Full Text
- View/download PDF
218. Evaluation of gene expression signatures predictive of cytogenetic and molecular subtypes of pediatric acute myeloid leukemia
- Author
-
Balgobind, B.V. (Brian), Heuvel-Eibrink, M.M. (Marry) van den, Menezes, R.X. (Renee) de, Reinhardt, D. (Dirk), Hollink, I.H.I.M. (Iris), Arentsen-Peters, T.C.J.M. (Susan), Wering, E.R. (Elisabeth) van, Kaspers, G.J.L. (Gertjan), Cloos, J. (Jacqueline), Bont, E.S.J.M. (Eveline) de, Cayuela, J.M. (Jean Michel), Baruchel, A. (André), Meyer, C. (Claus), Marschalek, R. (Rolf), Trka, J. (Jan), Stary, J. (Jan), Beverloo, H.B. (Berna), Pieters, R. (Rob), Zwaan, C.M. (Michel), Boer, M.L. (Monique) den, Balgobind, B.V. (Brian), Heuvel-Eibrink, M.M. (Marry) van den, Menezes, R.X. (Renee) de, Reinhardt, D. (Dirk), Hollink, I.H.I.M. (Iris), Arentsen-Peters, T.C.J.M. (Susan), Wering, E.R. (Elisabeth) van, Kaspers, G.J.L. (Gertjan), Cloos, J. (Jacqueline), Bont, E.S.J.M. (Eveline) de, Cayuela, J.M. (Jean Michel), Baruchel, A. (André), Meyer, C. (Claus), Marschalek, R. (Rolf), Trka, J. (Jan), Stary, J. (Jan), Beverloo, H.B. (Berna), Pieters, R. (Rob), Zwaan, C.M. (Michel), and Boer, M.L. (Monique) den
- Abstract
Background Pediatric acute myeloid leukemia is a heterogeneous disease characterized by non-random genetic aberrations related to outcome. The genetic subtype is currently detected by different diagnostic procedures which differ in success rate and/or specificity. Design and Methods We examined the potential of gene expression profiles to classify pediatric acute myeloid leukemia. Gene expression microarray data of 237 children with acute myeloid leukemia were collected and a double-loop cross validation approach was used to generate a subtype-predictive gene expression profile in the discovery cohort (n=157) which was then tested for its true predictive value in the independent validation cohort (n=80). The cla
- Published
- 2011
- Full Text
- View/download PDF
219. Prognostic significance of additional cytogenetic aberrations in 733 de novo pediatric 11q23/MLL-rearranged AML patients: Results of an international study
- Author
-
Coenen, E.A. (Eva), Raimondi, S. (Susana), Harbott, J. (Jochen), Zimmermann, M. (Martin), Beverloo, H.B. (Berna), Chang, M. (Myron), Creutzig, U. (Ursula), Dworzak, M.N. (Michael), Forestier, E. (Erik), Gibson, B. (Brenda), Hasle, H. (Henrik), Harrison, C.J. (Christine), Heerema, N.A. (Nyla), Kaspers, G.J.L. (Gertjan), Leszl, A. (Anna), Litvinko, N. (Nathalia), Nigro, L.L. (Luca), Morimoto, A. (Akira), Perot, C. (Christine), Auvrignon, A. (Anne), Reinhardt, D. (Dirk), Rubnitz, J.E. (Jeffrey), Smith, F.O. (Franklin), Stary, J. (Jan), Stasevich, I. (Irina), Strehl, S. (Sabine), Taga, T. (Takashi), Tomizawa, D. (Daisuke), Zemanová, Z. (Zuzana), Webb, D.K.H. (David), Alonzo, T.A. (Todd), Pieters, R. (Rob), Zwaan, C.M. (Michel), Heuvel-Eibrink, M.M. (Marry) van den, Coenen, E.A. (Eva), Raimondi, S. (Susana), Harbott, J. (Jochen), Zimmermann, M. (Martin), Beverloo, H.B. (Berna), Chang, M. (Myron), Creutzig, U. (Ursula), Dworzak, M.N. (Michael), Forestier, E. (Erik), Gibson, B. (Brenda), Hasle, H. (Henrik), Harrison, C.J. (Christine), Heerema, N.A. (Nyla), Kaspers, G.J.L. (Gertjan), Leszl, A. (Anna), Litvinko, N. (Nathalia), Nigro, L.L. (Luca), Morimoto, A. (Akira), Perot, C. (Christine), Auvrignon, A. (Anne), Reinhardt, D. (Dirk), Rubnitz, J.E. (Jeffrey), Smith, F.O. (Franklin), Stary, J. (Jan), Stasevich, I. (Irina), Strehl, S. (Sabine), Taga, T. (Takashi), Tomizawa, D. (Daisuke), Zemanová, Z. (Zuzana), Webb, D.K.H. (David), Alonzo, T.A. (Todd), Pieters, R. (Rob), Zwaan, C.M. (Michel), and Heuvel-Eibrink, M.M. (Marry) van den
- Abstract
We previously demonstrated that outcome of pediatric 11q23/MLL-rearranged AML depends on the translocation partner (TP). In this multicenter international study on 733 children with 11q23/MLL-rearranged AML, we further analyzed which additional cytogenetic aberrations (ACA) had prognostic significance. ACAs occurred in 344 (47%) of 733 and were associated with unfavorable outcome (5-year overall survival [OS] 47% vs 62%, P < .001). Trisomy 8, the most frequent specific ACA (n = 130/344, 38%), independently predicted favorable outcome within the ACAs group (OS 61% vs 39%, P = .003; Cox model for OS hazard ratio (HR) 0.54, P = .03), on the basis of reduced relapse rate (26% vs 49%, P < .001). Trisomy 19 (n = 37/344, 11%) independently predicted poor prognosis in ACAs cases, which was partly caused by refractory disease (remission rate 74% vs 89%, P = .04; OS 24% vs 50%, P < .001; HR 1.77, P = .01). Structural ACAs had independent adverse prognostic value for event-free survival (HR 1.36, P = .01). Complex karyotype, defined as ≥ 3 abnormalities, was present in 26% (n = 192/733) and showed worse outcome than those without complex karyotype (OS 45% vs 59%, P = .003) in univariate analysis only. In conclusion, like TP, specific ACAs have independent prognostic significance in pediatric 11q23/MLL-rearranged AML, and the mechanism underlying these prognostic differences should be studied.
- Published
- 2011
- Full Text
- View/download PDF
220. Integrative analysis of type-I and type-II aberrations underscores the genetic heterogeneity of pediatric acute myeloid leukemia
- Author
-
Balgobind, BV (Brian), Hollink, Iris, Peters, Susan, Zimmermann, M, Harbott, J, Beverloo, Berna, von Bergh, ARM, Cloos, J, Kaspers, GJL, de Haas, V, Zemanova, Z, Stary, J, Cayuela, JM, Baruchel, A, Creutzig, U, Reinhardt, D, Pieters, Rob, Zwaan, C.M., Van den Heuvel - Eibrink, Marry, Balgobind, BV (Brian), Hollink, Iris, Peters, Susan, Zimmermann, M, Harbott, J, Beverloo, Berna, von Bergh, ARM, Cloos, J, Kaspers, GJL, de Haas, V, Zemanova, Z, Stary, J, Cayuela, JM, Baruchel, A, Creutzig, U, Reinhardt, D, Pieters, Rob, Zwaan, C.M., and Van den Heuvel - Eibrink, Marry
- Published
- 2011
221. Evaluation of gene expression signatures predictive of cytogenetic and molecular subtypes of pediatric acute myeloid leukemia
- Author
-
Balgobind, BV (Brian), Van den Heuvel - Eibrink, Marry, Menezes, Renee, Reinhardt, D, Hollink, Iris, Peters, Susan, van Wering, ER, Kaspers, GJL, Cloos, J, de Bont, ESJM, Cayuela, JM, Baruchel, A, Meyer, C, Marschalek, R, Trka, J, Stary, J, Beverloo, Berna, Pieters, Rob, Zwaan, C.M., den Boer, Monique, Balgobind, BV (Brian), Van den Heuvel - Eibrink, Marry, Menezes, Renee, Reinhardt, D, Hollink, Iris, Peters, Susan, van Wering, ER, Kaspers, GJL, Cloos, J, de Bont, ESJM, Cayuela, JM, Baruchel, A, Meyer, C, Marschalek, R, Trka, J, Stary, J, Beverloo, Berna, Pieters, Rob, Zwaan, C.M., and den Boer, Monique
- Published
- 2011
222. Efficacy and Safety of Imatinib on Top of BFM-Like Chemotherapy in Pediatric Patients with Ph+/BCR-ABL+ Acute Lymphoblastic Leukemia (Ph+ALL). the EsPhALL Study
- Author
-
Biondi, A, Schrappe, M, Di Lorenzo, P, Castor, A, Lucchini, G, Gandemer, V, Pieters, R, Stary, J, Escherich, G, Campbell, M, Kong-Li, C, Vora, A, Lonnerholm, G, Arico, M, Harbott, J, Saha, V, Valsecchi, M, Biondi, A, Schrappe, M, Di Lorenzo, P, Castor, A, Lucchini, G, Gandemer, V, Pieters, R, Stary, J, Escherich, G, Campbell, M, Kong-Li, C, Vora, A, Lonnerholm, G, Arico, M, Harbott, J, Saha, V, and Valsecchi, M
- Published
- 2011
223. Second induction with high-dose cytarabine and mitoxantrone: different impact on pediatric AML patients with t(8;21) and with inv(16)
- Author
-
Creutzig, U, Zimmermann, M, Bourquin, J P, Dworzak, M N, von Neuhoff, C, Sander, A, Schrauder, A, Teigler-Schlegel, A, Stary, J, Corbacioglu, S, Reinhardt, D, Creutzig, U, Zimmermann, M, Bourquin, J P, Dworzak, M N, von Neuhoff, C, Sander, A, Schrauder, A, Teigler-Schlegel, A, Stary, J, Corbacioglu, S, and Reinhardt, D
- Abstract
Patients with core binding factor acute myeloid leukemia (CBF-AML) benefit from more intensive chemotherapy, but whether both the t(8;21) and inv(16)/t (16;16) subtypes requires intensification remained to be determined. In the 2 successive studies (AML-BFM-1998 and AML-BFM-2004), 220 CBF-AML patients were treated using the same chemotherapy backbone, whereby reinduction with high-dose cytarabine and mitoxantrone (HAM) was scheduled for these cohorts only in study AML-BFM-1998 but not in AML-BFM-2004 against the background to minimize overtreatment. Five-year overall survival (OS) and event-free survival (EFS) were significantly higher and the cumulative incidence of relapse (CIR) lower in t(8;21) patients treated with HAM (n = 78) compared with without HAM (n = 53): OS 92% ± 3% versus 80% ± 6%, p(logrank)0.047, EFS 84% ± 4% versus 59% ± 7%, p(logrank)0.001, and CIR 14% ± 4% versus 34% ± 7%, p((gray))0.006. These differences were not seen for inv(16) (n = 43 and 46, respectively): OS 93% ± 4% versus 94% ± 4%, EFS 75% ± 7% versus 71% ± 9% and CIR 15% ± 6% versus 23% ± 8% (not significant). The subtype t(8;21), but not inv(16), was an independent predictor of worse outcome without HAM reinduction. Based on our data, a 5-year OS of > 90% can be expected for CBF-AML, when stratifying t(8;21), but not inv(16), patients to high-risk chemotherapy, including HAM reinduction.
- Published
- 2011
224. Myelodysplastic syndrome, juvenile myelomonocytic leukemia, and acute myeloid leukemia associated with complete or partial monosomy 7. European Working Group on MDS in Childhood (EWOG-MDS)
- Author
-
Hasle, H., Arico, M., Basso, G., Biondi, A., Cantu Rajnoldi, A., Creutzig, U., Fenu, S., Fonatsch, C., Haas, O. A., Harbott, J., Kardos, G., Kerndrup, G., Mann, G., Niemeyer, C. M., Ptoszkova, H., Ritter, J., Slater, R., Stary, J., Stollmann Gibbels, B., Testi, Anna Maria, Van Wering, E. R., and Zimmermann, M.
- Subjects
Male ,Infant ,Leukemia, Myelomonocytic, Chronic ,Survival Rate ,Monosomy ,Leukemia, Myeloid ,Child, Preschool ,Myelodysplastic Syndromes ,Acute Disease ,Humans ,Female ,Genetic Predisposition to Disease ,Child ,Chromosomes, Human, Pair 7 - Abstract
We reviewed the clinical features, treatment, and outcome of 100 children with myelodysplastic syndrome (MDS), juvenile myelomonocytic leukemia (JMML), and acute myeloid leukemia (AML) associated with complete monosomy 7 (-7) or deletion of the long arm of chromosome 7 (7q-). Patients with therapy-induced disease were excluded. The morphologic diagnoses according to modified FAB criteria were: MDS in 72 (refractory anemia (RA) in 11, RA with excess of blasts (RAEB) in eight, RAEB in transformation (RAEB-T) in 10, JMML in 43), and AML in 28. The median age at presentation was 2.8 years (range 2 months to 15 years), being lowest in JMML (1.1 year). Loss of chromosome 7 as the sole cytogenetic abnormality was observed in 75% of those with MDS compared with 32% of those with AML. Predisposing conditions (including familial MDS/AML) were found in 20%. Three-year survival was 82% in RA, 63% in RAEB, 45% in JMML, 34% in AML, and 8% in RAEB-T. Children with -7 alone had a superior survival than those with other cytogenetic abnormalities: this was solely due to a better survival in MDS (3-year survival 56 vs 24%). The reverse was found in AML (3-year survival 13% in -7 alone vs 44% in other cytogenetic groups). Stable disease for several years was documented in more than half the patients with RA or RAEB. Patients with RA, RAEB or JMML treated with bone marrow transplantation (BMT) without prior chemotherapy had a 3-year survival of 73%. The morphologic diagnosis was the strongest prognostic factor. Only patients with a diagnosis of JMML fitted what has previously been referred to as the monosomy 7 syndrome. Our data give no support to the concept of monosomy 7 as a distinct syndrome.
- Published
- 1999
225. EVI1 overexpression in distinct subtypes of pediatric acute myeloid leukemia.
- Author
-
Balgobind, B.V., Lugthart, S., Hollink, I.H., Arentsen-Peters, S.T., Wering, E.R. van, Graaf, S.S.N. de, Reinhardt, D., Creutzig, U., Kaspers, G.J.L., Bont, E.S. de, Stary, J., Trka, J., Zimmermann, M., Beverloo, H.B., Pieters, R., Delwel, R., Zwaan, C.M., Heuvel-Eibrink, M.M. van den, Balgobind, B.V., Lugthart, S., Hollink, I.H., Arentsen-Peters, S.T., Wering, E.R. van, Graaf, S.S.N. de, Reinhardt, D., Creutzig, U., Kaspers, G.J.L., Bont, E.S. de, Stary, J., Trka, J., Zimmermann, M., Beverloo, H.B., Pieters, R., Delwel, R., Zwaan, C.M., and Heuvel-Eibrink, M.M. van den
- Abstract
1 mei 2010, Item does not contain fulltext, Overexpression of the ecotropic virus integration-1 (EVI1) gene (EVI1+), localized at chromosome 3q26, is associated with adverse outcome in adult acute myeloid leukemia (AML). In pediatric AML, 3q26 abnormalities are rare, and the role of EVI1 is unknown. We studied 228 pediatric AML samples for EVI1+ using gene expression profiling and RQ-PCR. EVI1+ was found in 20/213 (9%) of children with de novo AML, and in 4/8 with secondary AML. It was predominantly found in MLL-rearranged AML (13/47), monosomy 7 (2/3), or FAB M6/7 (6/10), and mutually exclusive with core-binding factor AML, t(15;17), and NPM1 mutations. Fluorescent in situ hybridization (FISH) was performed to detect cryptic 3q26 abnormalities. However, none of the EVI1+ patients harbored structural 3q26 alterations. Although significant differences in 4 years pEFS for EVI1+ and EVI1- pediatric AML were observed (28%+/-11 vs 44%+/-4, P=0.04), multivariate analysis did not identify EVI1+ as an independent prognostic factor. We conclude that EVI1+ can be found in approximately 10% of pediatric AML. Although EVI1+ was not an independent prognostic factor, it was predominantly found in subtypes of pediatric AML that are related with an intermediate to unfavorable prognosis. Further research should explain the role of EVI1+ in disease biology in these cases. Remarkably, no 3q26 abnormalities were identified in EVI1+ pediatric AML.
- Published
- 2010
226. Low frequency of MLL-partial tandem duplications in paediatric acute myeloid leukaemia using MLPA as a novel DNA screenings technique.
- Author
-
Balgobind, B.V., Hollink, I.H., Reinhardt, D., Wering, E.R. van, Graaf, S.S.N. de, Baruchel, A., Stary, J., Beverloo, H.B., Greef, G.E. de, Pieters, R., Zwaan, C.M., Heuvel-Eibrink, M.M. van den, Balgobind, B.V., Hollink, I.H., Reinhardt, D., Wering, E.R. van, Graaf, S.S.N. de, Baruchel, A., Stary, J., Beverloo, H.B., Greef, G.E. de, Pieters, R., Zwaan, C.M., and Heuvel-Eibrink, M.M. van den
- Abstract
01 juli 2010, Item does not contain fulltext, Mixed-lineage leukaemia (MLL)-partial tandem duplications (PTDs) are found in 3-5% of adult acute myeloid leukaemia (AML), and are associated with poor prognosis. In adult AML, MLL-PTD is only detected in patients with trisomy 11 or internal tandem duplications of FLT3 (FLT3-ITD). To date, studies in paediatric AML are scarce, and reported large differences in the frequency of MLL-PTD, frequently utilising mRNA RT-PCR only to detect MLL-PTDs. We studied the frequency of MLL-PTD in a large cohort of paediatric AML (n=276) and the results from two different methods, i.e. mRNA RT-PCR, and multiplex ligation-dependent probe amplification (MLPA), a method designed to detect copy number differences of specific DNA sequences. In some patients with an MLL-rearrangement, MLL-PTD transcripts were detected, but were not confirmed by DNA-MLPA, indicating that DNA-MLPA can more accurately detect MLL-PTD compared to mRNA RT-PCR. In paediatric AML, MLL-PTD was detected in 7/276 patients (2.5%). One case had a trisomy 11, while the others had normal cytogenetics. Furthermore 4 of the 7 patients revealed a FLT3-ITD, which was significantly higher compared with the other AML cases (p=0.016). In conclusion, using DNA-MLPA as a novel screenings technique in combination with mRNA RT-PCR a low frequency of MLL-PTD in paediatric AML was found. Larger prospective studies are needed to further define the prognostic relevance of MLL-PTD in paediatric AML.
- Published
- 2010
227. Complex karyotype newly defined: The strongest prognostic factor in advanced childhood myelodysplastic syndrome
- Author
-
Göhring, G. (Gudrun), Michalova, K. (Kyra), Beverloo, H.B. (Berna), Betts, D. (David), Harbott, J. (Jochen), Haas, O.A. (Oskar), Kerndrup, G. (Gitte), Sainati, L. (Laura), Bergstraesser, E. (Eva), Hasle, H. (Henrik), Stary, J. (Jan), Trebo, M. (Monica), Heuvel-Eibrink, M.M. (Marry) van den, Zecca, M. (Marco), Wering, E.R. (Elisabeth) van, Fischer, A. (Alexandra), Noellke, P. (Peter), Strahm, B. (Brigitte), Locatelli, F. (Franco), Niemeyer, C.M. (Charlotte), Schlegelberger, B. (Brigitte), Göhring, G. (Gudrun), Michalova, K. (Kyra), Beverloo, H.B. (Berna), Betts, D. (David), Harbott, J. (Jochen), Haas, O.A. (Oskar), Kerndrup, G. (Gitte), Sainati, L. (Laura), Bergstraesser, E. (Eva), Hasle, H. (Henrik), Stary, J. (Jan), Trebo, M. (Monica), Heuvel-Eibrink, M.M. (Marry) van den, Zecca, M. (Marco), Wering, E.R. (Elisabeth) van, Fischer, A. (Alexandra), Noellke, P. (Peter), Strahm, B. (Brigitte), Locatelli, F. (Franco), Niemeyer, C.M. (Charlotte), and Schlegelberger, B. (Brigitte)
- Abstract
To identify cytogenetic risk factors predicting outcome in children with advanced myelodysplastic syndrome, overall survival of 192 children prospectively enrolled in European Working Group of Myelodysplastic Syndrome in Childhood studies was evaluated with regard to karyotypic complexity. Structurally complex constitutes a new definition of complex karyotype characterized by more than or equal to 3 chromosomal aberrations, including at least one structural aberration. Five-year overall survival in patients with more than or equal to 3 clonal aberrations, which were not structurally complex, did not differ from that observed in patients with normal karyotype. Cox regression analysis revealed the presence of a monosomal and structurally complex karyotype to be strongly associated with poor prognosis (hazard ratio = 4.6, P < .01). Notably, a structurally complex karyotype without a monosomy was associated with a very short 2-year overall survival probability of only 14% (hazard ratio = 14.5; P < .01). The presence of a structurally complex karyotype was the strongest independent prognostic marker predicting poor outcome in children with advanced myelodysplastic syndrome.
- Published
- 2010
- Full Text
- View/download PDF
228. Improved outcome with hematopoietic stem cell transplantation in a poor prognostic subgroup of infants with mixed-lineage-leukemia (MLL)-rearranged acute lymphoblastic leukaemia: results from the Interfant-99 Study
- Author
-
Mann, G, Attarbaschi, A, Schrappe, M, De Lorenzo, P, Peters, C, Hann, I, De Rossi, G, Felice, M, Lausen, B, Leblanc, T, Szczepanski, T, Ferster, A, Janka Schaub, G, Rubnitz, J, Silverman, L, Stary, J, Campbell, M, Li, C, Suppiah, R, Biondi, A, Vora, A, Valsecchi, M, Pieters, R, Silverman, LB, Li, CK, Pieters, R., BIONDI, ANDREA, VALSECCHI, MARIA GRAZIA, Mann, G, Attarbaschi, A, Schrappe, M, De Lorenzo, P, Peters, C, Hann, I, De Rossi, G, Felice, M, Lausen, B, Leblanc, T, Szczepanski, T, Ferster, A, Janka Schaub, G, Rubnitz, J, Silverman, L, Stary, J, Campbell, M, Li, C, Suppiah, R, Biondi, A, Vora, A, Valsecchi, M, Pieters, R, Silverman, LB, Li, CK, Pieters, R., BIONDI, ANDREA, and VALSECCHI, MARIA GRAZIA
- Abstract
To define a role for hematopoietic stem cell transplantation (HSCT) in infants with acute lymphoblastic leukemia (ALL) and rearrangements of the mixed-lineageleukemia gene (MLL+) we compared the outcome of MLL+ patients from trial Interfant-99 who either received chemotherapy only or HSCT. Of 376 patients with a known MLL status in the trial, 297 (79%) were MLL+. Among the 277/297 MLL+ patients (93%) in first remission (CR), there appeared to be a significant difference in disease-free survival (adjusted by waiting time to HSCT) between the 37 (13%) who received HSCT and the 240 (87%) who received chemotherapy only (P=0.03). However, the advantage was restricted to a subgroup with two additional unfavourable prognostic features: age <6 months and either poor response to steroids at day 8 or leukocytes ≥300 G/L. Ninety-seven/297 MLL+ patients (33%) had such high-risk criteria, with 87 achieving CR. In this group HSCT was associated with a 64% reduction in the risk of failure due to relapse or death in CR (HR=0.36, 95% CI: 0.15-0.86). In the remaining patients, there was no advantage for HSCT over chemotherapy only. In summary, HSCT seems to be a valuable option for a subgroup of infant MLL+ ALL carrying further poor prognostic factors. The trial was registered with http://ClinicalTrials.gov (NCT 00015873) and at http://controlledtrials. com (ISRCTN24251487).
- Published
- 2010
229. Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: Results of an international retrospective study
- Author
-
Balgobind, B.V. (Brian), Raimondi, S.C. (Susana), Harbott, J. (Jochen), Zimmermann, M. (Martin), Alonzo, T.A. (Todd), Auvrignon, A. (Anne), Beverloo, H.B. (Berna), Chang, M. (Myron), Creutzig, U., Dworzak, M.N. (Michael), Forestier, E. (Erik), Gibson, B. (Brenda), Hasle, H. (Henrik), Harrison, C.J. (Christine), Heerema, N.A. (Nyla), Kaspers, G.J.L. (Gertjan), Leszl, A. (Anna), Litvinko, N. (Nathalia), Nigro, L.L. (Luca), Morimoto, A. (Akira), Perot, C. (Christine), Pieters, R. (Rob), Reinhardt, D. (Dirk), Rubnitz, J.E. (Jeffrey), Smith, F.O. (Franklin), Stary, J. (Jan), Stasevich, I. (Irina), Strehl, S., Taga, T. (Takashi), Tomizawa, D. (Daisuke), Webb, D.K.H. (David), Zemanova, Z. (Zuzana), Zwaan, C.M. (Michel), Heuvel-Eibrink, M.M. (Marry) van den, Balgobind, B.V. (Brian), Raimondi, S.C. (Susana), Harbott, J. (Jochen), Zimmermann, M. (Martin), Alonzo, T.A. (Todd), Auvrignon, A. (Anne), Beverloo, H.B. (Berna), Chang, M. (Myron), Creutzig, U., Dworzak, M.N. (Michael), Forestier, E. (Erik), Gibson, B. (Brenda), Hasle, H. (Henrik), Harrison, C.J. (Christine), Heerema, N.A. (Nyla), Kaspers, G.J.L. (Gertjan), Leszl, A. (Anna), Litvinko, N. (Nathalia), Nigro, L.L. (Luca), Morimoto, A. (Akira), Perot, C. (Christine), Pieters, R. (Rob), Reinhardt, D. (Dirk), Rubnitz, J.E. (Jeffrey), Smith, F.O. (Franklin), Stary, J. (Jan), Stasevich, I. (Irina), Strehl, S., Taga, T. (Takashi), Tomizawa, D. (Daisuke), Webb, D.K.H. (David), Zemanova, Z. (Zuzana), Zwaan, C.M. (Michel), and Heuvel-Eibrink, M.M. (Marry) van den
- Abstract
Translocations involving chromosome 11q23 frequently occur in pediatric acute myeloid leukemia (AML) and are associated with poor prognosis. In most cases, the MLL gene is involved, and more than 50 translocation partners have been described. Clinical outcome data of the 11q23-rearranged subgroups are scarce because most 11q23 series are too small for meaningful analysis of subgroups, although some studies suggest that patients with t(9;11)(p22;q23) have a more favorable prognosis. We retrospectively collected outcome data of 756 children with 11q23- or MLL-rearranged AML from 11 collaborative groups to identify differences in outcome based on translocation partners. All karyotypes were centrally reviewed before assigning patients to subgroups. The event-free survival of 11q23/ MLL-rearranged pediatric AML at 5 years from diagnosis was 44%(± 5%), with large differences across subgroups (11% ± 5%to 92% ± 5%). Multivariate analysis identified the following subgroups as independent prognostic predictors: t(1;11)(q21;q23) (hazard ratio [HR] = 0.1, P = .004); t(6; 11)(q27;q23) (HR = 2.2, P < .001); t(10; 11)(p12;q23) (HR = 1.5, P = .005); and t(10;11)(
- Published
- 2009
- Full Text
- View/download PDF
230. Pharmacokinetics of high-dose methotrexate in infants treated for acute lymphoblastic leukemia
- Author
-
Lönnerholm, G, Valsecchi, M, De Lorenzo, P, Schrappe, M, Hovi, L, Campbell, M, Mann, G, Janka Schaub, G, Li, C, Stary, J, Hann, I, Pieters, R, Pieters, R., VALSECCHI, MARIA GRAZIA, Lönnerholm, G, Valsecchi, M, De Lorenzo, P, Schrappe, M, Hovi, L, Campbell, M, Mann, G, Janka Schaub, G, Li, C, Stary, J, Hann, I, Pieters, R, Pieters, R., and VALSECCHI, MARIA GRAZIA
- Abstract
Interfant-99 was an international collaborative treatment protocol for infants with acute lymphoblastic leukemia (ALL).
- Published
- 2009
231. Outcome of congenital acute lymphoblastic leukemia treated on the Interfant-99 protocol
- Author
-
van der Linden, M, Valsecchi, M, De Lorenzo, P, Möricke, A, Janka, G, Leblanc, T, Felice, M, Biondi, A, Campbell, M, Hann, I, Rubnitz, J, Stary, J, Szczepanski, T, Vora, A, Ferster, A, Hovi, L, Silverman, L, Pieters, R, van der Linden, MH, Leblanc, TM, BIONDI, ANDREA, Rubnitz, JE, Silverman, LB, Pieters, R., VALSECCHI, MARIA GRAZIA, van der Linden, M, Valsecchi, M, De Lorenzo, P, Möricke, A, Janka, G, Leblanc, T, Felice, M, Biondi, A, Campbell, M, Hann, I, Rubnitz, J, Stary, J, Szczepanski, T, Vora, A, Ferster, A, Hovi, L, Silverman, L, Pieters, R, van der Linden, MH, Leblanc, TM, BIONDI, ANDREA, Rubnitz, JE, Silverman, LB, Pieters, R., and VALSECCHI, MARIA GRAZIA
- Abstract
Acute lymphoblastic leukemia (ALL) diagnosed in the first month of life (congenital ALL) is very rare. Although congenital ALL is often assumed to be fatal, no studies have been published on outcome except for case reports. The present study reports the outcome of 30 patients with congenital ALL treated with the uniform Interfant-99 protocol, a hybrid regimen combining ALL treatment with elements designed for treatment of acute myeloid leukemia. Congenital ALL was characterized by a higher white blood cell count and a strong trend for higher incidence of MLL rearrangements and CD10-negative B-lineage ALL compared with older infants. Induction failure rate was 13% and not significantly different from that in older infants (7%, P = .14), but relapse rate was significantly higher in congenital ALL patients (2-year cumulative incidence [SE] was 60.0 [9.3] vs 34.2 [2.3], P < .001). Two-year event-free survival and survival of congenital ALL patients treated with this protocol was 20% (SE 9.1%). Early death in complete remission and treatment delays resulting from toxicity were not different. The survival of 17% after last follow-up, combined with a toxicity profile comparable with that in older infants, justifies treating congenital ALL with curative intent. This trial was registered at www.clinicaltrials.gov as no. NCT 00015873, and at www.controlled-trials.com as no. ISRCTN24251487.
- Published
- 2009
232. Mutations in CBL occur frequently in juvenile myelomonocytic leukemia
- Author
-
Loh, M L, Sakai, D S, Flotho, C, Kang, M, Fliegauf, M, Archambeault, S, Mullighan, C G, Chen, L, Bergstraesser, E, Bueso-Ramos, C E, Emanuel, P D, Hasle, H, Issa, J P, van den Heuvel-Eibrink, M M, Locatelli, F, Stary, J, Trebo, M, Wlodarski, M, Zecca, M, Shannon, K M, Niemeyer, C M, Loh, M L, Sakai, D S, Flotho, C, Kang, M, Fliegauf, M, Archambeault, S, Mullighan, C G, Chen, L, Bergstraesser, E, Bueso-Ramos, C E, Emanuel, P D, Hasle, H, Issa, J P, van den Heuvel-Eibrink, M M, Locatelli, F, Stary, J, Trebo, M, Wlodarski, M, Zecca, M, Shannon, K M, and Niemeyer, C M
- Abstract
Juvenile myelomonocytic leukemia is an aggressive myeloproliferative disorder characterized by malignant transformation in the hematopoietic stem cell compartment with proliferation of differentiated progeny. Seventy-five percent of patients harbor mutations in the NF1, NRAS, KRAS, or PTPN11 genes, which encode components of Ras signaling networks. Using single nucleotide polymorphism arrays, we identified a region of 11q isodisomy that contains the CBL gene in several JMML samples, and subsequently identified CBL mutations in 27 of 159 JMML samples. Thirteen of these mutations alter codon Y371. In this report, we also demonstrate that CBL and RAS/PTPN11 mutations were mutually exclusive in these patients. Moreover, the exclusivity of CBL mutations with respect to other Ras pathway-associated mutations indicates that CBL may have a role in deregulating this key pathway in JMML.
- Published
- 2009
233. T-cell receptor Vbeta CDR3 oligoclonality frequently occurs in childhood refractory cytopenia (MDS-RC) and severe aplastic anemia
- Author
-
Vries, A.C. de, Langerak, A.W., Verhaaf, B., Niemeyer, C.M., Stary, J., Schmiegelow, K., Wering, E.R. van, Zwaan, C.M., Beishuizen, A., Pieters, R., MM, van den Heuvel-Eibrink, Vries, A.C. de, Langerak, A.W., Verhaaf, B., Niemeyer, C.M., Stary, J., Schmiegelow, K., Wering, E.R. van, Zwaan, C.M., Beishuizen, A., Pieters, R., and MM, van den Heuvel-Eibrink
- Abstract
(Very) severe acquired aplastic anemia ((v)SAA) and myelodysplastic syndrome (MDS) are rare diseases in childhood. (V)SAA is a bone marrow (BM) failure syndrome characterized by immune-mediated destruction of hematopoietic progenitors. MDS is a malignant clonal stem cell disorder, of which the hypoplastic variant is, in case of absence of a cytogenetic clone, difficult to separate from (v)SAA. Recently, studies provided a molecular signature of autoimmunity in adult (v)SAA, by showing oligoclonality based on the length of the TCR Vbeta CDR3 region. We investigated retrospectively the frequency and the discriminative value of TCR Vbeta CDR3 oligoclonality in pediatric (v)SAA and MDS patients. Peripheral blood (PB) and/or BM mononuclear cell samples of pediatric patients with (v)SAA (n=38), refractory cytopenia (MDS-RC) (n=28) and 18 controls were analysed via TCR Vbeta heteroduplex PCR analysis of extracted RNA. A skewed TCR Vbeta CDR3 repertoire was found in 21/38 (v)SAA and in 17/28 RC patients in contrast to 2/18 in the control group. These data suggest an overlapping group of RC and SAA patients that may share a common immune-mediated pathogenesis. Prospective studies are required to establish the clinical value of TCR Vbeta CDR3 repertoire analysis to predict the clinical response in these patients Udgivelsesdato: 2008/6
- Published
- 2008
234. Eligibility for allogeneic transplantation in very high risk childhood acute lymphoblastic leukemia: The impact of the waiting time
- Author
-
Balduzzi, A, De Lorenzo, P, Schrauder, A, Conter, V, Uderzo, C, Peters, C, Klingebiel, T, Stary, J, Felice, M, Magyarosy, E, Schrappe, M, Dini, G, Gadner, H, Valsecchi, M, Schrauder A, Felice, MS, VALSECCHI, MARIA GRAZIA, Balduzzi, A, De Lorenzo, P, Schrauder, A, Conter, V, Uderzo, C, Peters, C, Klingebiel, T, Stary, J, Felice, M, Magyarosy, E, Schrappe, M, Dini, G, Gadner, H, Valsecchi, M, Schrauder A, Felice, MS, and VALSECCHI, MARIA GRAZIA
- Abstract
The advantage of allogeneic transplant from compatible related donors versus chemotherapy in children with very-high-risk acute lymphoblastic leukemia in first complete remission was previously demonstrated in an international prospective trial. This study quantified the impact of time elapsed in first remission in the same cohort. Of 357 pediatric patients with very-high-risk acute lymphoblastic leukemia, 259 received chemotherapy, 55 transplantation from compatible related and 43 from unrelated donors. The 5-year disease-free survival was 44.2% overall and 42.5% for chemotherapy only patients. The chemotherapy conditional 5-year disease-free survival increased to 44.4%, 47.6%, 51.7%, and 60.4% in patients who maintained their first remission for at least 3, 6, 9, and 12 months respectively. The overall outcome was superior to that obtained with chemotherapy-only at any time-point. The relative advantage of transplant from compatible related donors in very-high-risk childhood acute lymphoblastic leukemia was consistent for any time elapsed in first remission.
- Published
- 2008
235. Comparison of horse and rabbit antithymocyte globulin in immunosuppressive therapy for refractory cytopenia of childhood
- Author
-
Yoshimi, A., primary, van den Heuvel-Eibrink, M. M., additional, Baumann, I., additional, Schwarz, S., additional, Simonitsch-Klupp, I., additional, de Paepe, P., additional, Campr, V., additional, Kerndrup, G. B., additional, O'Sullivan, M., additional, Devito, R., additional, Leguit, R., additional, Hernandez, M., additional, Dworzak, M., additional, de Moerloose, B., additional, Stary, J., additional, Hasle, H., additional, Smith, O. P., additional, Zecca, M., additional, Catala, A., additional, Schmugge, M., additional, Locatelli, F., additional, Fuhrer, M., additional, Fischer, A., additional, Guderle, A., additional, Nollke, P., additional, Strahm, B., additional, and Niemeyer, C. M., additional
- Published
- 2013
- Full Text
- View/download PDF
236. The clinical relevance of minor paroxysmal nocturnal hemoglobinuria clones in refractory cytopenia of childhood: a prospective study by EWOG-MDS
- Author
-
Aalbers, A M, primary, van der Velden, V H J, additional, Yoshimi, A, additional, Fischer, A, additional, Noellke, P, additional, Zwaan, C M, additional, Baumann, I, additional, Beverloo, H B, additional, Dworzak, M, additional, Hasle, H, additional, Locatelli, F, additional, De Moerloose, B, additional, Göhring, G, additional, Schmugge, M, additional, Stary, J, additional, Zecca, M, additional, Langerak, A W, additional, van Dongen, J J M, additional, Pieters, R, additional, Niemeyer, C M, additional, and van den Heuvel-Eibrink, M M, additional
- Published
- 2013
- Full Text
- View/download PDF
237. Pulses of vincristine and dexamethasone in addition to intensive chemotherapy for children with intermediate-risk acute lymphoblastic leukaemia: a multicentre randomised trial
- Author
-
Conter, V, Valsecchi, M, Silvestri, D, Campbell, M, Dibar, E, Magyarosy, E, Gadner, H, Stary, J, Benoit, Y, Zimmermann, M, Reiter, A, Riehm, H, Masera, G, Schrappe, M, Gadner H, Schrappe, M., VALSECCHI, MARIA GRAZIA, MASERA, GIUSEPPE, Conter, V, Valsecchi, M, Silvestri, D, Campbell, M, Dibar, E, Magyarosy, E, Gadner, H, Stary, J, Benoit, Y, Zimmermann, M, Reiter, A, Riehm, H, Masera, G, Schrappe, M, Gadner H, Schrappe, M., VALSECCHI, MARIA GRAZIA, and MASERA, GIUSEPPE
- Abstract
Background: Studies in the 1970s and 1980s suggested that the outcome of childhood acute lymphoblastic leukaemia (ALL) could be improved by intensification of conventional continuation chemotherapy with pulses of vincristine sulfate and steroids. We aimed to investigate the efficacy and toxic effects of vincristine-dexamethasone pulses as an addition to the continuation-therapy phase in a large cohort of children with intermediate-risk disease who were treated with the Berlin-Frankfurt-Münster (BFM) treatment strategy. Methods: 3109 children, diagnosed with ALL and intermediate-risk features, were enrolled by eight participating organisations in eleven countries. All were treated with very similar protocols based on the BFM treatment strategy, which included induction, consolidation, reinduction, and continuation-therapy phases. At the beginning of the continuation-therapy phase, those patients in complete remission were randomly assigned to either a treatment or a control group. Control patients were given conventional mercaptopurine and methotrexate chemotherapy only. Patients in the treatment arm were also given pulses of vincristine (1·5 mg/m2 weekly for 2 weeks) and dexamethasone (6 mg/m2 daily for 7 days) every 10 weeks for six cycles. The primary outcome measure was disease-free survival. Analysis was by intention to treat. The study is registered at http://www.clinicaltrials.gov with the identifier NCT00411541. Findings: 174 patients (5·6%) relapsed or died in complete remission before randomisation. Of the remaining 2935 patients, 2618 (89·2%) were randomly assigned: 1325 to the treatment group and 1293 to the control group. With median follow-up of 4·8 years, 240 children in the treatment group and 241 in the control group had relapses; 15 in the treatment group and 14 controls died in complete remission or developed second malignant neoplasms. The 5-year and 7-year disease-free survival estimates were 79·8% (SE 1·2) and 77·5% (1·5)
- Published
- 2007
238. A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial
- Author
-
Pieters, R, Schrappe, M, De Lorenzo, P, Hann, I, De Rossi, G, Felice, M, Hovi, L, Leblanc, T, Szczepanski, T, Ferster, A, Janka, G, Rubnitz, J, Silverman, L, Stary, J, Campbell, M, Li, C, Mann, G, Suppiah, R, Biondi, A, Vora, A, Valsecchi, M, LeBlanc, T, Li, CK, BIONDI, ANDREA, VALSECCHI, MARIA GRAZIA, Pieters, R, Schrappe, M, De Lorenzo, P, Hann, I, De Rossi, G, Felice, M, Hovi, L, Leblanc, T, Szczepanski, T, Ferster, A, Janka, G, Rubnitz, J, Silverman, L, Stary, J, Campbell, M, Li, C, Mann, G, Suppiah, R, Biondi, A, Vora, A, Valsecchi, M, LeBlanc, T, Li, CK, BIONDI, ANDREA, and VALSECCHI, MARIA GRAZIA
- Abstract
Background Acute lymphoblastic leukaemia in infants younger than 1 year is rare, and infants with the disease have worse outcomes than do older children. We initiated an international study to investigate the effects of a new hybrid treatment protocol with elements designed to treat both acute lymphoblastic: leukaemia and acute myeloid leukaemia, and to identify any prognostic factors for outcome in infants. We also did a randomised trial to establish the value of a late intensification course. Methods Patients aged 0-12 months were enrolled by 17 study groups in 22 countries between 1999 and 2005. Eligible patients were stratified for risk according to their peripheral blood response to a 7-day prednisone prophase, and then given a hybrid regimen based on the standard protocol for acute lymphoblastic leukaemia, with some elements designed for treatment of acute myeloid leukaemia. Before the maintenance phase, a subset of patients in complete remission were randomly assigned to receive either standard treatment or a more intensive chemotherapy course with high-dose cytarabine and methotrexate. The primary outcomes were event-free survival (EFS) for the initial cohort of patients and disease-free survival (DFS) for the patients randomly assigned to a treatment group. Data were analysed on an intention-to-treat basis. This trial was registered with ClinicalTrials.gov, number NCT 00015873, and at controlled-trials.com, number ISRCTN24251487. Findings In the 482 enrolled patients who underwent hybrid treatment, 260 (58%) were in complete remission at a median follow-up of 38 (range 1-78) months, and EFS at 4 years was 47.0% (SE 2.6, 95% CI 41.9-52.1). Of 445 patients in complete remission after 5 weeks of induction treatment, 191 were randomised: 95 patients to receive a late intensification course, and 96 to a control group. At a median follow-up of 42 (range 1-73) months, 60 patients in the treatment group and 57 controls were disease-free. DFS at 4 years did not diff
- Published
- 2007
239. Role of allogeneic bone marrow transplantation for the treatment of myelodysplastic syndromes in childhood. The European Working Group on Childhood Myelodysplastic Syndrome (EWOG-MDS) and the Austria-Germany-Italy (AGI) Bone Marrow Transplantation Registry
- Author
-
Locatelli F, Zecca M, Niemeyer C, Angelucci E, Arcese G, Bender-Gotze C, Bonetti F, Burdach S, Dini G, Ebell W, Friedrich W, Henrik Hasle, Hermann J, Jacobsen N, Klingebiel T, Kremens B, Mann G, Miniero R, Pession A, Peters C, Paolucci P, Rossetti F, Hj, Schmid, Stary J, and Zimmermann M
- Subjects
Male ,Treatment Outcome ,Adolescent ,Child, Preschool ,Myelodysplastic Syndromes ,Humans ,Infant ,Transplantation, Homologous ,Female ,allogeneic bone marrow transplantation ,myelodysplastic syndrome ,children ,Child ,Bone Marrow Transplantation - Published
- 1996
240. Chemotherapy versus allogeneic transplantation for very-high-risk childhood acute lymphoblastic leukaemia in first complete remission: Comparison by genetic randomisation in an international prospective study
- Author
-
Balduzzi, A, Valsecchi, M, Uderzo, C, De Lorenzo, P, Klingebiel, T, Peters, C, Stary, J, Felice, M, Magyarosy, E, Conter, V, Reiter, A, Messina, C, Gadner, H, Schrappe, M, VALSECCHI, MARIA GRAZIA, Felice, MS, Schrappe, M., Balduzzi, A, Valsecchi, M, Uderzo, C, De Lorenzo, P, Klingebiel, T, Peters, C, Stary, J, Felice, M, Magyarosy, E, Conter, V, Reiter, A, Messina, C, Gadner, H, Schrappe, M, VALSECCHI, MARIA GRAZIA, Felice, MS, and Schrappe, M.
- Abstract
Background The dismal prognosis of very-high-risk childhood acute lymphoblastic leukaemia could be improved by allogeneic haemopoietic cell transplantation. We compared this strategy with intensified chemotherapy protocols, with the aim to improve the outcome of children with very-high-risk acute lymphoblastic leukaemia in first complete remission. Methods A cooperative prospective study was set up in seven countries. Very-high-risk acute lymphoblastic leukaemia in first complete remission was defined by the presence of at least one of the following criteria: (1) failure to achieve complete remission after the first four-drug induction phase; (2) t(9;22) or t(4;11) clonal abnormalities; and (3) poor response to prednisone associated with T immunophenotype, white-blood-cell count of 100x10(9)/L or greater, or both. Children were allocated treatment by genetic chance, according to the availability of a compatible related donor, and assigned chemotherapy or haemopoietic-cell transplantation. The primary outcome was disease-free survival and analysis was by intention to treat. Findings Between April, 1995, and December, 2000, 357 children entered the study, of whom 280 were assigned chemotherapy and 77 related-donor haemopoietic-cell transplantation. 5-year disease-free survival was 40.6% (SE 3.1) in children allocated chemotherapy and 56.7% (5.7) in those assigned transplantation (hazard ratio 0.67 [95% CI 0.46-0.99]; p=0.02); 5-year survival was 50.1% (3.1) and 56.4% (5.9), respectively (0.73 [0.49-1.09]; p=0.12). Interpretation Children with very-high-risk acute lymphoblastic leukaemia benefit from related-donor haemopoietic-cell transplantation compared with chemotherapy. The gap between the two strategies increases as the risk profile of the patient worsens., BACKGROUND: The dismal prognosis of very-high-risk childhood acute lymphoblastic leukaemia could be improved by allogeneic haemopoietic cell transplantation. We compared this strategy with intensified chemotherapy protocols, with the aim to improve the outcome of children with very-high-risk acute lymphoblastic leukaemia in first complete remission. METHODS: A cooperative prospective study was set up in seven countries. Very-high-risk acute lymphoblastic leukaemia in first complete remission was defined by the presence of at least one of the following criteria: (1) failure to achieve complete remission after the first four-drug induction phase; (2) t(9;22) or t(4;11) clonal abnormalities; and (3) poor response to prednisone associated with T immunophenotype, white-blood-cell count of 100x10(9)/L or greater, or both. Children were allocated treatment by genetic chance, according to the availability of a compatible related donor, and assigned chemotherapy or haemopoietic-cell transplantation. The primary outcome was disease-free survival and analysis was by intention to treat. FINDINGS: Between April, 1995, and December, 2000, 357 children entered the study, of whom 280 were assigned chemotherapy and 77 related-donor haemopoietic-cell transplantation. 5-year disease-free survival was 40.6% (SE 3.1) in children allocated chemotherapy and 56.7% (5.7) in those assigned transplantation (hazard ratio 0.67 [95% CI 0.46-0.99]; p=0.02); 5-year survival was 50.1% (3.1) and 56.4% (5.9), respectively (0.73 [0.49-1.09]; p=0.12). INTERPRETATION: Children with very-high-risk acute lymphoblastic leukaemia benefit from related-donor haemopoietic-cell transplantation compared with chemotherapy. The gap between the two strategies increases as the risk profile of the patient worsens.
- Published
- 2005
241. Evaluation of WT1 expression in bone marrow vs peripheral blood samples of children with acute myeloid leukemia—impact on minimal residual disease detection
- Author
-
Kramarzova, K, primary, Boublikova, L, additional, Stary, J, additional, and Trka, J, additional
- Published
- 2012
- Full Text
- View/download PDF
242. The clinical relevance of BAALC and ERG expression levels in pediatric AML
- Author
-
Hermkens, M C H, primary, van den Heuvel-Eibrink, M M, additional, Arentsen-Peters, S T C J M, additional, Baruchel, A, additional, Stary, J, additional, Reinhardt, D, additional, Zimmerman, M, additional, de Haas, V, additional, Pieters, R, additional, and Zwaan, C M, additional
- Published
- 2012
- Full Text
- View/download PDF
243. DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG)
- Author
-
Zaghloul, M., primary, Ahmed, S., additional, Eldebaway, E., additional, Mousa, A., additional, Amin, A., additional, Elkhateeb, N., additional, Sabry, M., additional, Ogiwara, H., additional, Morota, N., additional, Sufit, A., additional, Donson, A., additional, Birks, D., additional, Patel, P., additional, Foreman, N., additional, Handler, M., additional, Massimino, M., additional, Biassoni, V., additional, Gandola, L., additional, Schiavello, E., additional, Pecori, E., additional, Potepan, P., additional, Bach, F., additional, Janssens, G. O., additional, Jansen, M. H., additional, Lauwers, S. J., additional, Nowak, P. J., additional, Oldenburger, F. R., additional, Bouffet, E., additional, Saran, F., additional, van Ulzen, K. K., additional, van Lindert, E. J., additional, Schieving, J. H., additional, Boterberg, T., additional, Kaspers, G. J., additional, Span, P. N., additional, Kaanders, J. H., additional, Gidding, C. E., additional, Hargrave, D., additional, Bailey, S., additional, Howman, A., additional, Pizer, B., additional, Harris, D., additional, Jones, D., additional, Kearns, P., additional, Picton, S., additional, Wheatley, K., additional, Gibson, M., additional, Glaser, A., additional, Connolly, D., additional, Kawamura, A., additional, Nagashima, T., additional, Yamamoto, K., additional, Sakata, J., additional, Lober, R., additional, Freret, M., additional, Fisher, P., additional, Edwards, M., additional, Yeom, K., additional, Monje, M., additional, Jansen, M., additional, Aliaga, E. S., additional, Van Der Hoeven, E., additional, Van Vuurden, D., additional, Heymans, M., additional, Gidding, C., additional, De Bont, E., additional, Reddingius, R., additional, Peeters-Scholte, C., additional, van Meeteren, A. S., additional, Gooskens, R., additional, Granzen, B., additional, Paardekoper, G., additional, Janssens, G., additional, Noske, D., additional, Barkhof, F., additional, Vandertop, W. P., additional, Kaspers, G., additional, Saratsis, A., additional, Yadavilli, S., additional, Nazarian, J., additional, Mitra, S., additional, Mallick, S., additional, Kim, J., additional, Beachy, P., additional, Nobre, L., additional, Vasconcelos, F., additional, Lima, F., additional, Mattos, D., additional, Kuiven, N., additional, Lima, G., additional, Silveira, J., additional, Sevilha, M., additional, Lima, M. A., additional, Ferman, S., additional, Leblond, P., additional, Lansiaux, A., additional, Rialland, X., additional, Gentet, J.-C., additional, Geoerger, B., additional, Frappaz, D., additional, Aerts, I., additional, Bernier-Chastagner, V., additional, Shah, R., additional, Zaky, W., additional, Grimm, J., additional, Bluml, S., additional, Wong, K., additional, Dhall, G., additional, Caretti, V., additional, Schellen, P., additional, Lagerweij, T., additional, Bugiani, M., additional, Navis, A., additional, Wesseling, P., additional, Noske, D. P., additional, Wurdinger, T., additional, Lee, H., additional, Ziegler, D., additional, Schroeder, K., additional, Huang, E., additional, Berlow, N., additional, Patel, R., additional, Becher, O., additional, Taylor, I., additional, Mao, X.-g., additional, Hutt, M., additional, Weingart, M., additional, Kahlert, U., additional, Maciacyk, J., additional, Nikkhah, G., additional, Eberhart, C., additional, Raabe, E., additional, Barton, K., additional, Misuraca, K., additional, Zhou, Z., additional, Rotman, L., additional, Ho, S., additional, Souweidane, M., additional, Lim, K. J., additional, Warren, K., additional, Chang, H., additional, Lightner, D., additional, Haque, S., additional, Khakoo, Y., additional, Dunkel, I., additional, Gilheeney, S., additional, Kramer, K., additional, Lyden, D., additional, Wolden, S., additional, Greenfield, J., additional, De Braganca, K., additional, Ting-Rong, H., additional, Muh-Li, L., additional, Kai-Ping, C., additional, Tai-Tong, W., additional, Hsin-Hung, C., additional, Kebudi, R., additional, Cakir, F. B., additional, Agaoglu, F. Y., additional, Gorgun, O., additional, Dizdar, Y., additional, Ayan, I., additional, Darendeliler, E., additional, Zapotocky, M., additional, Churackova, M., additional, Malinova, B., additional, Kodet, R., additional, Kyncl, M., additional, Tichy, M., additional, Stary, J., additional, Sumerauer, D., additional, Minturn, J., additional, Shu, H.-K., additional, Fisher, M., additional, Patti, R., additional, Janss, A., additional, Allen, J., additional, Phillips, P., additional, Belasco, J., additional, Taylor, K., additional, Baudis, M., additional, von Beuren, A., additional, Fouladi, M., additional, and Jones, C., additional
- Published
- 2012
- Full Text
- View/download PDF
244. Haematopoetic stem cell transplantation for refractory autoimmune cytopenia.
- Author
-
Passweg, J R, Rabusin, M, Musso, M, Beguin, Y, Cesaro, S, Ehninger, G, Espigado, I, Iriondo, A, Jost, L, Koza, V, Lenhoff, S, Lisukov, I, Locatelli, F, Marmont, A, Philippe, P, Pilatrino, C, Quartier, P, Stary, J, Veys, P, Vormoor, J, Wahlin, Anders, Zintl, F, Bocelli-Tyndall, C, Tyndall, A, Gratwohl, A, Passweg, J R, Rabusin, M, Musso, M, Beguin, Y, Cesaro, S, Ehninger, G, Espigado, I, Iriondo, A, Jost, L, Koza, V, Lenhoff, S, Lisukov, I, Locatelli, F, Marmont, A, Philippe, P, Pilatrino, C, Quartier, P, Stary, J, Veys, P, Vormoor, J, Wahlin, Anders, Zintl, F, Bocelli-Tyndall, C, Tyndall, A, and Gratwohl, A
- Published
- 2004
- Full Text
- View/download PDF
245. Minimal residual disease in peripheral blood at day 15 identifies a subgroup of childhood B-cell precursor acute lymphoblastic leukemia with superior prognosis
- Author
-
Volejnikova, J., primary, Mejstrikova, E., additional, Valova, T., additional, Reznickova, L., additional, Hodonska, L., additional, Mihal, V., additional, Sterba, J., additional, Jabali, Y., additional, Prochazkova, D., additional, Blazek, B., additional, Hak, J., additional, Cerna, Z., additional, Hrusak, O., additional, Stary, J., additional, Trka, J., additional, and Fronkova, E., additional
- Published
- 2011
- Full Text
- View/download PDF
246. Integrative analysis of type-I and type-II aberrations underscores the genetic heterogeneity of pediatric acute myeloid leukemia
- Author
-
Balgobind, B. V., primary, Hollink, I. H. I. M., additional, Arentsen-Peters, S. T. C. J. M., additional, Zimmermann, M., additional, Harbott, J., additional, Beverloo, H. B., additional, von Bergh, A. R. M., additional, Cloos, J., additional, Kaspers, G. J. L., additional, de Haas, V., additional, Zemanova, Z., additional, Stary, J., additional, Cayuela, J.-M., additional, Baruchel, A., additional, Creutzig, U., additional, Reinhardt, D., additional, Pieters, R., additional, Zwaan, C. M., additional, and van den Heuvel-Eibrink, M. M., additional
- Published
- 2011
- Full Text
- View/download PDF
247. 232 Relevance of WT1 expression, mutations and single nucleotide polymorphisms in juvenile myelomonocytic leukemia
- Author
-
de Vries, A., primary, Zwaan, M., additional, Hollink, I., additional, Willasch, A., additional, Alders, M., additional, de Haas, V., additional, Dworzak, M., additional, Hasle, H., additional, Locatelli, F., additional, Zecca, M., additional, de Moerloose, B., additional, Stary, J., additional, Niemeyer, C., additional, Flotho, C., additional, Bader, P., additional, Pieters, R., additional, and van den Heuvel-Eibrink, M., additional
- Published
- 2011
- Full Text
- View/download PDF
248. 233 IER3 in childhood myelodysplastic syndrome
- Author
-
de Vries, A., primary, Zwaan, M., additional, de Haas, V., additional, Hasle, H., additional, Locatelli, F., additional, de Moerloose, B., additional, Polychronopoulou, S., additional, Stary, J., additional, Schmugge-Liner, M., additional, Zecca, M., additional, Beverloo, B., additional, Niemeyer, C., additional, Pieters, R., additional, and van den Heuvel-Eibrink, M., additional
- Published
- 2011
- Full Text
- View/download PDF
249. Evaluation of gene expression signatures predictive of cytogenetic and molecular subtypes of pediatric acute myeloid leukemia
- Author
-
Balgobind, B. V., primary, Van den Heuvel-Eibrink, M. M., additional, De Menezes, R. X., additional, Reinhardt, D., additional, Hollink, I. H. I. M., additional, Arentsen-Peters, S. T. J. C. M., additional, van Wering, E. R., additional, Kaspers, G. J. L., additional, Cloos, J., additional, de Bont, E. S. J. M., additional, Cayuela, J.-M., additional, Baruchel, A., additional, Meyer, C., additional, Marschalek, R., additional, Trka, J., additional, Stary, J., additional, Beverloo, H. B., additional, Pieters, R., additional, Zwaan, C. M., additional, and den Boer, M. L., additional
- Published
- 2010
- Full Text
- View/download PDF
250. Prognosis of children with mixed phenotype acute leukemia treated on the basis of consistent immunophenotypic criteria
- Author
-
Mejstrikova, E., primary, Volejnikova, J., additional, Fronkova, E., additional, Zdrahalova, K., additional, Kalina, T., additional, Sterba, J., additional, Jabali, Y., additional, Mihal, V., additional, Blazek, B., additional, Cerna, Z., additional, Prochazkova, D., additional, Hak, J., additional, Zemanova, Z., additional, Jarosova, M., additional, Oltova, A., additional, Sedlacek, P., additional, Schwarz, J., additional, Zuna, J., additional, Trka, J., additional, Stary, J., additional, and Hrusak, O., additional
- Published
- 2010
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.